Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study

BACKGROUND: Higher serum concentrations of vedolizumab have been associated with improved outcomes in inflammatory bowel disease. It is unclear how vedolizumab exposure is linked to endoscopic remission in Crohn disease (CD). We aimed to develop a pharmacokinetic-pharmacodynamic model linking vedoli...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanzel, Jurij, Dreesen, Erwin, Vermeire, Séverine, Löwenberg, Mark, Hoentjen, Frank, Bossuyt, Peter, Clasquin, Esmé, Baert, Filip J, D’Haens, Geert R, Mathôt, Ron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071095/
https://www.ncbi.nlm.nih.gov/pubmed/34137430
http://dx.doi.org/10.1093/ibd/izab143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071095/
https://www.ncbi.nlm.nih.gov/pubmed/34137430
http://dx.doi.org/10.1093/ibd/izab143

Ejemplares similares